Raafat Abdel-Malek

Raafat Abdel-Malek

Auto-generated profile, based on publicly available information

Raafat Abdel-Malek

Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
LKLoay Kassem
Loay Kassem
KSKyrillus S. Shohdy
Kyrillus S. Shohdy
SLShaimaa Lasheen
Shaimaa Lasheen
OAOmar Abdel-Rahman
Omar Abdel-Rahman
AAAhmad Ali
Ahmad Ali
RARaafat R. Abdel-Malek
Raafat R. Abdel-Malek

1 April 2018 in Clinical Breast Cancer
Verified
Journal Article
Closed access
HAHamdy A. Azim
Hamdy A. Azim
RARaafat Abdel-Malek
Raafat Abdel-Malek
LKLoay Kassem
Loay Kassem

1 July 2018
Verified
Journal Article
Open access
PDF file
RARaafat Abdel-Malek
Raafat Abdel-Malek
RWRita Wassef
Rita Wassef
EREnas Rizk
Enas Rizk
HSHoda Sabry
Hoda Sabry
NTNevine Tadros
Nevine Tadros
ABAbdallah Boghdady
Abdallah Boghdady
Background: Toxoplasmosis is one of the most important cosmopolitan life-threatening diseases in immunecompromisedpatients. It is caused by an intracellular protozoon: Toxoplasma gondii (T. gondii). The parasite can causepneumonia, encephalitis or disseminated disease in immune-deficient patients and dangerous congenital anomaliesin infants born to mothers infected during early pregnancies. The present study aims to evaluate the prevalence oftoxoplasmosis in Egyptian cancer patients and to correlate the prevalence with type of malignancy and the differentcancer treatment modalities. Materials and Methods: Blood samples from 150 cancer patients and 50 control subjectshave been examined for presence of anti-toxoplasma antibodies using a lateral flow chromatographic immunoassay.Results: Among cancer patients included in this study, the prevalence of anti- T.gondii antibodies was 20% for IgGand 4% for IgM, while in the control group it was 8% and 2% in the same order. This difference was statisticallysignificant for IgG (P =0.003) but not for IgM (P = 0.44). Patients with solid organ tumors treated with chemotherapyhad the highest prevalence rate of toxoplasmosis (28%). It was also found higher in males (26%) than females (10%)and higher among urban (18%) than rural dwellers (16%). Conclusion: Cancer patients showed a significantly higherrate of infection with T. gondii than their cross-matched control. For that reason, we recommend the inclusion of ascreening test for toxoplasmosis in their routine workup.

22 October 2009 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
HAH. A. Azim
H. A. Azim
LSL. Santoro
L. Santoro
RBR. G. Bociek
R. G. Bociek
Sara GandiniSara Gandini
Sara Gandini
RMR. A. Malek
R. A. Malek
Background: Aggressive non-Hodgkin's lymphoma (NHL) represents ∼60% of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Nevertheless, still a significant fraction of patients is not offered rituximab due to economic reasons. Thus, CHOP is still offered to these patients as well as those with T-cell subtypes. Data from the early 1990s have indicated that the dose intensity (DI) of doxorubicin is a key factor in predicting survival. Methods: A Medline and Cochrane library search was carried out using the search terms ‘CHOP’, ‘lymphoma’ and ‘randomized trials’. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m2/week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95% confidence interval (CI) 0.71–0.96], event-free survival (SHR 0.86; 95% CI 0.75–0.99) and higher complete response rate (summary odds ratio 0.91; 95% CI 0.67–0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.

30 November 2018 in Journal of Parasitic Diseases
Verified
Journal Article
Closed access
PDF file
RWRita Wassef
Rita Wassef
RARaafat Abdel-Malek
Raafat Abdel-Malek

1 January 2019 in Indian Journal of Palliative Care
Verified
Journal Article
Open access
PDF file
KSKyrillus S Shohdy
Kyrillus S Shohdy
RARaafat Abdel-Malek
Raafat Abdel-Malek
DFDinaE Farag
DinaE Farag
SCSarah Cox
Sarah Cox
Objective: Family caregivers are the default caring personnel for terminal cancer patients. The characteristics, demographics, distribution, psychological burden, and socioeconomic standards differ between high- and low-income countries. We aimed to assess those factors and their direct reflection on both the patient and the caregiver. Patients and Methods: This is a comparative cross-sectional study for terminal cancer patients in the palliative care unit between the United Kingdom (UK) as a high-income community and Egypt as a low-income community. We assessed the different characteristics, demographics, living place, the degree of relevance, and the availability of caregivers. Results: We have recruited 216 patients from the UK and 117 patients from Egypt. Informal caregivers were available in 74.5% and 92.3% for these patients with a mean age of 71.5 (standard deviation [SD] 16) years and 50.9 (SD 15.18) years, respectively. There has been a statistically significant difference between the two countries' caregivers in being married, family, and living in the same household (P < 0.0001). Conclusion: Low-income countries are more common to have an informal caregiver who is a family member of different degree of relevance. Caregivers in low-income settings tend to be younger, of the female gender, married, and living in the same household than in high-income ones.